Replimune Group, Inc. (REPL) plunged 44.74 percent to $3.15 on Thursday, down$2.55, after the company said it had completed a Type A meeting with the U.S. Food and Drug Administration regarding the complete response letter tied to its Biologics License Application for RP1 in combination with nivolumab for advanced melanoma. The stock opened at $4.12 and traded between$3.15 and $4.44, compared with a prior close of$5.71 on the Nasdaq. Trading volume surged to 15.9 million shares, well above the average o ...